• Register
  • Login

European Journal of Molecular & Clinical Medicine

  • Home
  • Browse
    • Current Issue
    • By Issue
    • By Subject
    • Keyword Index
    • Author Index
    • Indexing Databases XML
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Indexing and Abstracting
    • Peer Review Process
    • News
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
Advanced Search

Notice

As part of Open Journals’ initiatives, we create website for scholarly open access journals. If you are responsible for this journal and would like to know more about how to use the editorial system, please visit our website at https://ejournalplus.com or
send us an email to info@ejournalplus.com

We will contact you soon

  1. Home
  2. Volume 9, Issue 1
  3. Author

Online ISSN: 2515-8260

Volume9, Issue1

A comparative study between 0.2% ropivacaine with dexmedetomidine and 0.125% levobupivacaine with dexmedetomidine for post-operative epidural analgesia in patients undergoing total abdominal hysterectomy

    Dr. T. Anusha,Dr. Kiran Kumar Suggala, Dr. Tejaswi T

European Journal of Molecular & Clinical Medicine, 2022, Volume 9, Issue 1, Pages 701-710

  • Show Article
  • Download
  • Cite
  • Statistics
  • Share

Abstract

Introduction: TAH is associated with significant post-operative pain. Epidural analgesia
with a variety of local anaesthetics and adjuvants is widely used for TAH as it provides both
intra and post-operative analgesia. The aim is to compare the effect of post-operative epidural
analgesia with 0.2% ropivacaine and dexmedetomidine versus 0.125% levobupivacaine and
dexmedetomidine in patients undergoing TAH.
Method: Afterobtaining ethical committee permission and patient consent, 50 women aged
35-65 years of ASA 1&2 were included in the study. We have excluded patients with
hypersensitivity to local anaesthetics, infection at the site of injection. Patients were divided
into 2 groups of 25 each. Group RD-received 10ml of 0.2% ropivacaine and
dexmedetomidine 1 mcg/kg. Group LD-received 10ml of 0.125% levobupivacaine and
dexmedetomidine 1mcg/kg. Using chi-square test and student t-test statistical results were
obtained.
Results: The mean onset of analgesia in Group RD was 11.86min and in Group LD was
8.468min which is statistically significant (P<0.05). Mean duration of analgesia in Group RD
was 210min and in Group LD was 271min which is statistically significant (P<0.05).
Conclusion: We conclude that 0.125% levobupivacaine with dexmedetomidine as adjuvant
was found to have faster onset and prolonged duration of analgesia than 0.2% ropivacaine
with dexmedetomidine.
Keywords:
    Epidural ropivacaine Levobupivacaine dexmedetomidine
  • PDF (414 K)
  • XML
(2022). A comparative study between 0.2% ropivacaine with dexmedetomidine and 0.125% levobupivacaine with dexmedetomidine for post-operative epidural analgesia in patients undergoing total abdominal hysterectomy. European Journal of Molecular & Clinical Medicine, 9(1), 701-710.
Dr. T. Anusha,Dr. Kiran Kumar Suggala, Dr. Tejaswi T. "A comparative study between 0.2% ropivacaine with dexmedetomidine and 0.125% levobupivacaine with dexmedetomidine for post-operative epidural analgesia in patients undergoing total abdominal hysterectomy". European Journal of Molecular & Clinical Medicine, 9, 1, 2022, 701-710.
(2022). 'A comparative study between 0.2% ropivacaine with dexmedetomidine and 0.125% levobupivacaine with dexmedetomidine for post-operative epidural analgesia in patients undergoing total abdominal hysterectomy', European Journal of Molecular & Clinical Medicine, 9(1), pp. 701-710.
A comparative study between 0.2% ropivacaine with dexmedetomidine and 0.125% levobupivacaine with dexmedetomidine for post-operative epidural analgesia in patients undergoing total abdominal hysterectomy. European Journal of Molecular & Clinical Medicine, 2022; 9(1): 701-710.
  • RIS
  • EndNote
  • BibTeX
  • APA
  • MLA
  • Harvard
  • Vancouver
  • Article View: 118
  • PDF Download: 164
  • LinkedIn
  • Twitter
  • Facebook
  • Google
  • Telegram
Journal Information

Publisher:

Email:  editor.ejmcm21@gmail.com

  • Home
  • Glossary
  • News
  • Aims and Scope
  • Privacy Policy
  • Sitemap

 

For Special Issue Proposal : editor.ejmcm21@gmail.com

This journal is licensed under a Creative Commons Attribution 4.0 International (CC-BY 4.0)

Powered by eJournalPlus